News in Brief

CDMO BioDuro acquires Molecular Response

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Kritchanut)
(Image: iStock/Kritchanut)
BioDuro has acquired Molecular Response LLC and its translational oncology research platform, which includes a biobank of more than 100,000 viable tumor specimens.

Based in San Diego-CA, Molecular Response’s platform includes a collection of viable tumor specimens, including tumor, immune, and stromal cells for in vitro​ and in vivo​ studies.

TJ Deng, general manager for BioDuro Discovery, said the company is committed to growing into a “complete chemistry and biology provider​,” adding, “unique platforms in oncology are a critical centerpiece of that strategy​."

According to the contract research and development organization (CDMO), the platform supports various drug discovery oncology and immune-oncology studies, including immunophenotyping screens and xenograft pharmacology studies.

"The Molecular Response acquisition immediately strengthens our capability and provides our clients a continuous set of capability, enabling our customers to start with our chemistry services through preclinical and translational oncology studies, all the way to IND,"​ he said in a press release.

Following the acquisition, terms of which were not disclosed, Molecular Response will operate as a wholly-owned subsidiary of BioDuro and will continue selling its biospecimens to strategic partners.

Molecular Response CEO, Thomas Broudy, PhD will become Executive Vice President, Translational Sciences and Strategy.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars